alexa Real World Use of Teriflunomide in South Africa: A Medium Prevalence Multiple Sclerosis Area | OMICS International| Abstract
ISSN: 2376-0389

Journal of Multiple Sclerosis
Open Access

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
  • Research Article   
  • J Mult Scler (Foster City) 2018, Vol 5(2): 222
  • DOI: 10.4172/2376-0389.1000222

Real World Use of Teriflunomide in South Africa: A Medium Prevalence Multiple Sclerosis Area

Britz M1, Fourie N2, Giampaolo DL3, Guldenpfennig CG4, Isaacs MD5, Opperman DC6, Pearl JC6, Retief CF2, Shamley DP7, Terblanche JM8 and Bhigjee AI9*
1Greenacres Medical Centre, 227 Cape Road, Mill Park, Port Elizabeth, 6045, South Africa
2Wilgers Medical Centre, 538 Denneboom Road, Die Wilgers, Pretoria, 0184, South Africa
3Netcare Rosebank Hospital, 14 Sturdee Avenue, Rosebank, Johannesburg, 2132, South Africa
4Life Groenkloof Hospital, George Storar Drive, Groenkloof, Pretoria, 0181, South Africa
5Mediclinic Cape Town Hospital, 21 Hof Street, Gardens, Cape Town, 8001, South Africa
6Netcare Sunninghill Hospital, Witkoppen and Nanyuki Road, Sunninghill, Sandton, 2196, South Africa
7Life Wilgeheuwel Hospital, Amplifier Road, Radiokop Extension 13, Roodepoort, 1724, South Africa
8Netcare Unitas Hospital, Clifton Avenue, Lyttelton Manor, Centurion, 0157, South Africa
9Department of Neurology, The Inkosi Albert Luthuli Central Hospital, 800 Vusi Mzimela Road, Mayville 4058, Durban, South Africa
*Corresponding Author : Bhigjee AI, Department of Neurology, The Inkosi Albert Luthuli Central Hospital, 800 Vusi Mzimela Road, Mayville 4058, Durban, South Africa, Tel: 27-31-250235963, Fax: 27-31-2402358, Email: [email protected]

Received Date: Dec 13, 2018 / Accepted Date: Dec 19, 2018 / Published Date: Dec 26, 2018


Back ground: South Africa, which has a multi-ethnic population of over fifty million, is considered to have a medium (5-30/100 000) prevalence rate of Multiple Sclerosis. Teriflunomide is one of two oral disease modifying agents that have been registered in this country. We describe the real-world experience of this drug in South Africa with respect to efficacy, tolerability and side effects.

Methods: A retrospective analysis was undertaken of the demographics, clinical presentation, number of preceding relapses, date of last relapse, degree of disability (Expanded Disability Status Scale–EDSS- score) and the magnetic resonance imaging (MRI) changes at initiation of therapy with teriflunomide (14 mg daily orally) and the subsequent course. Tolerability and side effects were recorded. Any preceding disease modifying therapy was recorded. The treating neurologists were asked about the effectiveness of teriflunomide in the patients under their care.

Results: Data for 32 patients was analysed. The majority were women (75%) and of white race (78.1%). The mean age (±SD) was 41.1 (11.5) years at the time of initial assessment. Twenty six of the 32 (81%) patients were on prior disease modifying therapy (DMT) which consisted of an interferon-beta 1a or 1b and glatiramer acetate. One patient was on teriflunomide at initiation of the study. The duration on treatment with DMTs prior to teriflunomide ranged from 7.0 to 236.6 months with a mean (±SD) of 96.5 (71.2) months.

The duration of therapy with teriflunomide varied from 3 to 24 months with a mean (±SD) of 12.3 (5.0) months. Fourteen patients experienced mild to moderate relapses while on teriflunomide treatment, with 56% remaining relapse free over the study period. The mean (±SD) EDSS score on teriflunomide was 2.5 (1.6), remaining relatively stable compared to the baseline score 2.6 (1.3). The drug was well tolerated in 24 patients, satisfactorily tolerated in 7 and not tolerated in 1. The treating neurologists’ assessment was that the drug was an effective treatment choice in 87.1% of patients, with 96.9% of patients remaining on therapy at the time of analysis. One patient experienced 2 relapses in the year of treatment and one experienced a relapse and progression of the gait disturbance.

Conclusions: This small “real world” study confirms that teriflunomide is an effective DMT for patients with mild to moderate MS, prolonged disease duration and switching from other DMTs. It has a tolerable side effect profile. The oral administration compared to the interferons will appeal to many patients. The drug was also effective in patients who were on previous DMTs.

Keywords: Multiple sclerosis; Teriflunomide oral therapy; Patient

Citation: Britz M, Fourie N, Giampaolo DL, Guldenpfennig CG, Isaacs MD, et al. (2018) Real World Use of Teriflunomide in South Africa: A Medium Prevalence Multiple Sclerosis Area. J Mult Scler (Foster City) 5: 222. Doi: 10.4172/2376-0389.1000222

Copyright: © 2018 Britz M, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Select your language of interest to view the total content in your interested language

Post Your Comment Citation
Share This Article
Relevant Topics
Article Usage
  • Total views: 2714
  • [From(publication date): 0-0 - Dec 15, 2019]
  • Breakdown by view type
  • HTML page views: 2622
  • PDF downloads: 92